Patent Law

PharmaBiotech IP 2008

By Stephen Albainy-Jenei

The Intellectual Property Owners association (IPO) recently reported on the fifteen possible Judiciary Committee Amendments to S. 1145, that were circulated by the Judiciary Committee last week. IPO noted that the amendments do not address the most hotly debated portions of the bill. Meanwhile, IPO believes Senate leaders will attempt to pass the much-delayed, massive patent reform bill S. 1145 in April or May.

The PharmaBiotech IP Summit held on May 28-30 at the Ritz-Carlton Philadelphia will be addressing how this reform could impact IP practitioners within the pharmaceutical & biotech industries. A high level panel featuring John T. Li from Novartis, Gary Creason from AVEO Pharmaceuticals and Robert Hrubiec from Cephalon will kick off the summit and focus on understanding the reform efforts and what the patent office is attempting to do.

Other speakers include Kathleen Fonda, Legal Advisor Office Of Patent Legal Administration, USPTO, James Gould from Schering-Plough, Robert Hrubiec, VP Intellectual Property and Chief Patent Counsel, Cephalon, Lee Caffin, DVP Global IP Strategy for Abbott Laboratories, and Luisa Bigornia, Vice President Intellectual Property, BioMarin Pharmaceutical.

What:  PharmaBiotech IP USA 2008:  Protect Critical Patents and Drive Sustainable Growth Through IP-Driven Business Strategies. 

When:  28-30 May, 2008. 

Where:  Ritz-Carlton Philadelphia, PA.

Full post as published by Patent Baristas on March 17, 2008 (boomark / email).